ArticleEClinicalMedicine2024
Projecting the clinical burden of chronic kidney disease at the patient level (
Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis.Renal failure · 2024Pooled it
- Effectiveness of Telehealth Low-Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real-World, Retrospective, Matched Cohort Study.Diabetes, obesity & metabolism · 2026Article
- The Chronic Kidney Disease Care Model: Quantifying Management Strategies for Improving Patient Outcomes in the USA.PharmacoEconomics - open · 2026Article
- The Impact of Non-AKI eGFR Variability on CKD Progression in Individuals With Type 2 Diabetes and Preserved Kidney Function.Kidney international reports · 2026Article
- Article
- Building healthier communities: effectiveness and cost-sustainability of the ASL3 GENESIS program for chronic diseases prevention.Aging clinical and experimental research · 2026Article
- Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings.Kidney medicine · 2026Article
- Effects of social determinants of health on the landscape of kidney disease.Nature reviews. Nephrology · 2026Review
- Chronic PMScientific reports · 2026Article
- PaCE CKD: A Multinational Survey of Financial Burden and Work Productivity in Patients with Chronic Kidney Disease and Caregivers.Advances in therapy · 2026Article
- International Environmental Impact of CKD Care.Kidney international reports · 2026Article
- Innovative Fatty Acid-Guided Biosensor Design for Neutrophil Gelatinase, a Prognostic and Diagnostic Biomarker for Chronic Kidney Disease.Biosensors · 2026Article
- Clarifying Molecular Mechanisms and Novel Strategies for Intervention of Uremia and Cognitive Decline.Kidney & blood pressure research · 2026Review
- Comparison of risks and costs of undiagnosed and diagnosed chronic kidney disease patients after the initiation of kidney replacement therapy in subsequent years. A Hungarian nationwide study.Frontiers in medicine · 2026Article
- Associations of Visceral Adiposity Index and Body Roundness Index with chronic kidney disease in a Hakka population: mediating effect of blood pressure.Frontiers in nutrition · 2026Article
- Article
- Disease Progression, Clinical Outcomes and Treatment Challenges in Patients with Chronic Kidney Disease and High-Risk Proteinuria.Advances in therapy · 2025Article
- A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration.Advances in therapy · 2025Article
- Reliable biomarkers for diabetic nephropathy using machine learning-assisted contrast-enhanced ultrasonography and clinical characteristics.Clinical and experimental medicine · 2025Article
- "Kidney international reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is a global concern that presents significant challenges for disease management. Several factors drive CKD prevalence, including primary risk factors, such as type 2 diabetes and hypertension, and an ageing population. Methods: Using a peer-reviewed microsimulation method, the clinical burden of CKD was estimated from 2022 to 2027. Demographic data from the Americas, Europe, and Asia-Pacific/Middle East were used to generate virtual populations and to project the prevalence of CKD, kidney replacement therapy, associated cardiovascular complications, comorbid conditions, and all-cause mortality in the CKD population over the modelled time frame. Findings: Across the 31 participating countries/regions, the total prevalence of CKD was projected to rise to 436.6 million cases by 2027 (an increase of 5.8% from 2022), with most cases (∼80%) undiagnosed. Interpretation: The clinical impact of CKD is substantial and likely to increase; the high prevalence of undiagnosed cases and associated complications may benefit from the implementation of health policy interventions that promote screening, earlier diagnosis, and interventions to improve outcomes. Funding: AstraZeneca.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.